

Drug Use Review (DUR) Board approves changes for Physician Administered Drugs (PAD)

The Nevada Medicaid Drug Use Review (DUR) Board met on April 17, 2025 and voted to adopt the following changes to Physician Administered Drugs (PAD) criteria, effective August 4, 2025.

Drug Class/Program	Background and Explanation of Policy Changes, Clarifications and Updates
Physician Administered Drugs (PAD)	Updated the following Physician Administered Drugs (PAD) classes: • Abraxane® (paclitaxel albumin bound) • Anti-PD-1 Monoclonal • Beovu® (brolucizumab-dbll) • Avastin®, Mvasi®, Zirabev™, Alymsys®, Vegzelma™, Avzivi® (bevacizumab) • Darzalex® (daratumumab) • Darzalex Faspro® - (daratumumab and hyaluronidase-fihj) • Elaprase® (idursulfase) • Anti-Angiogenic Ophthalmic Agents: Eylea®, Eylea® HD (intravitreal) • Antineoplastic-Anti-Programmed Cell Death Receptor-1 (PD-1) • Aranesp® (darbepoetin alfa) • Pemetrexed Alimta®, Pemfexy™, Pemetrexed • CD20 Monoclonal Antibodies • Yervoy® (ipilimumab) • Long-Acting Granulocyte Colony Stimulating Factors (LA-gCSF): Neulasta®; Fulphila®, Udenyca®; Ziextenzo®; Nyvepria™; Fylnetra®; Stimufend®; Rolvedon®; Ryzneuta®; Pegfilgrastim-fpgk

Prior Authorization forms may be found on the below webpage:
<https://gatewaypa.com/> (medical pharmacy/physician administered drugs)